RCT, Blinded, 2-Arm Efficacy Study of IP and Placebo in Patients With Chronic Pain Related to Osteoarthritis of the Knee

PHASE3UnknownINTERVENTIONAL
Enrollment

500

Participants

Timeline

Start Date

December 10, 2021

Primary Completion Date

August 31, 2022

Study Completion Date

October 19, 2022

Conditions
Degenerative Arthritis
Interventions
DRUG

Placebo

The 800mg ibuprofen sustained-release tablet is the same as the next generation of ibuprofen sustained-release tablets developed by foreign pharmaceutical companies, but does not contain a placebo that the active ingredient of ibuprofen

DRUG

Ibuprofen modified release tablet 800 mg

Medication: ibuprofen modified sustained release tablets 800 mg Ibuprofen sustained Release Tablet 800mg is a new generation of ibuprofen developed by overseas pharmaceutical companies. It works fast and lasts for up to 12 hours. The dosing regimen was twice daily, 12 hours apart. Ibuprofen :2-\[4-(2-methylpropyl) phenyl\] propionic acid, nonselective nonsteroidal anti-inflammatory drug (NSAID).

Trial Locations (1)

33409

RECRUITING

Palm Beach Research Center, West Palm Beach

Sponsors
All Listed Sponsors
collaborator

Virginia Contract Research Organization Co., Ltd.

OTHER

lead

Overseas Pharmaceuticals, Ltd.

INDUSTRY

NCT05318521 - RCT, Blinded, 2-Arm Efficacy Study of IP and Placebo in Patients With Chronic Pain Related to Osteoarthritis of the Knee | Biotech Hunter | Biotech Hunter